Starbucks initiated, Expedia downgraded: Wall Street's top analyst calls

Analysts made several rating changes: Wolfe upgraded Paychex (PAYX) citing stable employment trends. UBS upgraded Union Pacific (UNP) to Buy with a $339 price target, expecting strong 2027 volume growth. Needham upgraded Rocket Pharmaceuticals (RCKT) to Buy with a $9 target after FDA reaffirmed study design. JPMorgan upgraded Credicorp (BAP) to Overweight with a $482 target, seeing strong EPS growth. Morgan Stanley downgraded Expedia (EXPE) to Underweight with a $235 target, citing weaker assets

Original reporting
Published Sep 16, 2026, 1:42 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 16, 2026, 2:50 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Starbucks initiated, Expedia downgraded: Wall Street's top analyst calls — source image
Decision brief

The 30-second read

$PAYXBullishLow
01

Why it matters

The mixed set of rating changes provides selective bullish signals but overall limited market-moving power.

02

Market read

The article aggregates rating actions, offering selective trade ideas but limited overall market impact.

03

What to watch

Potential impact of upcoming macro data (inflation, rates) could outweigh individual analyst actions.

Relevance 5/10Novelty 5/10Timing: today

Background

Analyst firms released a series of upgrades, downgrades, and new coverage initiations across a range of U.S. listed companies.

Company-level read

Ticker impact

$PAYXBullishMedium confidence
Context

Wolfe Research upgraded Paychex to Peer Perform, citing reduced estimate risk amid stable employment trends.

Expected impact

small upside

Evidence & confidence

Upgrade reduces downside risk, may attract buyers.

$UNPBullishMedium confidence
Context

UBS upgraded Union Pacific to Buy with a $339 price target, forecasting strong volume growth in 2027.

Expected impact

moderate upside

Evidence & confidence

Higher target and growth outlook may drive demand.

$RCKTBullishMedium confidence
Context

Needham upgraded Rocket Pharmaceuticals to Buy after FDA reaffirmed pivotal study design for RP‑A501.

Expected impact

moderate upside

Evidence & confidence

FDA reaffirmation reduces clinical risk.

$SMWBBullishMedium confidence
Context

Needham upgraded Similarweb to Buy, citing AI potential to increase data value.

Expected impact

small upside

Evidence & confidence

Analyst sees AI as a catalyst.

$BAPBullishMedium confidence
Context

JPMorgan upgraded Credicorp to Overweight, raising price target to $482.

Expected impact

moderate upside

Evidence & confidence

Improved outlook despite regional risks.

$EXPEBearishMedium confidence
Context

Morgan Stanley downgraded Expedia to Underweight, citing weaker consumer assets and valuation premium.

Expected impact

downside risk

Evidence & confidence

Analyst concerns on fundamentals and valuation.

$MTHBearishMedium confidence
Context

Truist downgraded Meritage Homes to Hold, lowering price target to $72.

Expected impact

slight downside

Evidence & confidence

Increased risk of incentive ramping.

$HIGBearishMedium confidence
Context

Mizuho downgraded Hartford to Neutral, citing underwriting pressure and mix shift.

Expected impact

moderate downside

Evidence & confidence

Profitability concerns may affect stock.

Market effects

Broad coverage upgrades/downgrades may slightly shift sentiment in consumer, tech, and financial sectors.

U.S. equities may see modest activity across multiple sectors.

Limited; primarily U.S. market focus.

Counterpoint

Many upgrades could be premature given macro headwinds; investors may wait for earnings confirmation.

Key entities

  • Wolfe Research

    Upgraded Paychex

  • UBS

    Upgraded Union Pacific

  • Needham

    Upgraded Rocket Pharmaceuticals and Similarweb

  • JPMorgan

    Upgraded Credicorp

  • Morgan Stanley

    Downgraded Expedia

Related articles

$CLLSMedAI 8/10

Cellectis Earnings Call Highlights In Vivo Editing Shift

Cellectis (CLLS) reported Q3 earnings, highlighting a shift to in vivo gene editing. Preclinical results for HEAL-101 and HEAL-201 showed promise, with HEAL-101 reducing APOC3 levels by 67% and triglycerides by 76% in mice. The company expects clinical data in 2027-2028. Revenue fell to $19.9M, but net income improved to a $5.2M gain. Cash runway extends into 2H 2028. Management also announced workforce reductions and discontinued legacy programs.

$NUMedAI 8/10

Nu Holdings jumps about 12% as investors back its US launch while the Nasdaq falls

Nu Holdings (NU) rose 11.8% to $13.22 on Nov 13, despite a 0.9% Nasdaq drop. The neobank reported Q3 net income of $1.1B (up 31% FX-neutral) on $6.3B revenue, with 143M customers. Investors cheered its US launch, offering a 3.5% APY savings account and 1.5% cashback credit card, targeting Latin American communities. Nu aims to limit US expansion costs to 100 basis points through 2027.

$NUHighAI 8/10

Nu Holdings Earnings Call Highlights Record Growth

Nu Holdings (NU) reported Q3 earnings with record customer growth (143M), revenue ($6.3B, +37% YoY), and net income ($1.1B, +31%). Brazil remains core, while Mexico and Colombia show strong growth. Nu U.S. and Nu Global launched, with controlled investment budgets. Delinquencies rose slightly, and management highlighted disciplined underwriting.

$NUHigh

Brazil Clears Nubank to Buy a Bank License

Brazil's central bank approved Nubank's purchase of Banco Porto Real, granting it a banking license. Nubank (NU) expects to complete the deal soon, allowing it to use 'bank' in its name. The tiny bank had $5.7M in assets. Nubank's shares rose 11.8% Friday, closing at $13.22.